The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Phase II Study of Imatinib Mesylate Plus Hydroxyurea in Adults With Recurrent Glioblastoma Multiforme
Abstract
Purpose: We performed a phase II study to evaluate the combination of imatinib mesylate, an adenosine triphosphate mimetic, tyrosine kinase inhibitor, plus hydroxyurea, a ribonucleotide reductase inhibitor, in patients with recurrent glioblastoma multiforme (GBM). Patients and Methods: Patients with GBM at any recurrence received imatinib mesylate plus hydroxyurea (500 mg twice a day) orally on a continuous, daily schedule. The imatinib mesylate dose was 500 mg twice a day for patients on enzyme-inducing antiepileptic drugs (EIAEDs) and 400 mg once a day for those not on EIAEDs. Assessments were performed every 28 days. The primary end point was 6-month progression-free survival (PFS). Results: Thirty-three patients enrolled with progressive disease after prior radiotherapy and at least temozolomide-based chemotherapy. With a median follow-up of 58 weeks, 27% of patients were progression-free at 6 months, and the median PFS was 14.4 weeks. Three patients (9%) achieved radiographic response, and 14 (42%) achieved stable disease. Cox regression analysis identified concurrent EIAED use and no more than one prior progression as independent positive prognostic factors of PFS. The most common toxicities included grade 3 neutropenia (16%), thrombocytopenia (6%), and edema (6%). There were no grade 4 or 5 events. Concurrent EIAED use lowered imatinib mesylate exposure. Imatinib mesylate clearance was decreased at day 28 compared with day 1 in all patients, suggesting an effect of hydroxyurea. Conclusion: Imatinib mesylate plus hydroxyurea is well tolerated and associated with durable antitumor activity in some patients with recurrent GBM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011573 · Cited by 2,019
Cools, J., DeAngelo, D. J., Gotlib, J., Stover, E. H., Legare, R. D., Cortes, J., Kutok, J., Clark, J., Galinsky, I., Griffin, J. D., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025217 · Cited by 1,718
Browder, T. D., Butterfield, C., Kräling, B. M., Shi, B., Marshall, B., OʼReilly, M., & Folkman, J. (2000) · PubMed · Cited by 1,543
The anti-angiogenic basis of metronomic chemotherapy
Kerbel, R. S., & Kamen, B. A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1369 · Cited by 1,397
Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E., & Hanahan, D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17929 · Cited by 1,370
Sawyers, C. L. (2002) · Blood · doi:10.1182/blood.v99.10.3530 · Cited by 1,146
Analytical Methods Validation: Bioavailability, Bioequivalence, and Pharmacokinetic Studies
Shah, V. P., Midha, K. K., Dighe, S., McGilveray, I. J., Skelly, J. P., Yacobi, A., Layloff, T., Viswanathan, C. T., Edgar Cook, C., Mcdowall, R. D., et al. (1992) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600810324 · Cited by 1,121
Talpaz, M. (2002) · Blood · doi:10.1182/blood.v99.6.1928 · Cited by 1,019
Yung, W. K. A., Albright, R. E., Olson, J., Fredericks, R., Fink, K., Prados, M. D., Brada, M., Spence, A., Hohl, R. J., Shapiro, W., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1316 · Cited by 929
Self-citationA Confidence Interval for the Median Survival Time
Brookmeyer, R., & Crowley, J. (1982) · Biometrics · doi:10.2307/2530286 · Cited by 914
Outcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical Trials
Wong, E. T., Hess, K. R., Gleason, M. J., Jaeckle, K. A., Kyritsis, A. P., Prados, M. D., Levin, V. A., & Yung, W. K. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2572 · Cited by 902
Phase II Trial of Gefitinib in Recurrent Glioblastoma
Rich, J. N., Reardon, D. A., Peery, T., Dowell, J. M., Quinn, J. A., Penne, K. L., Wikstrand, C. J., Van Duyn, L. B., Dancey, J. E., McLendon, R. E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.110 · Cited by 734
Self-citationHermanson, M., Funa, N. S., Hartman, M., Claesson, L., Heldin, C., Westermark, B., & Nistér, M. (1992) · PubMed · Cited by 705
Apperley, J. F., Gardembas, M., Melo, J. V., Russell-Jones, R., Bain, B. J., Baxter, E. J., Chase, A., Chessells, J. M., Colombat, M., Dearden, C. E., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020150 · Cited by 630
(1991) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/bf03189968 · Cited by 614
SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
Laird, A., Vajkoczy, P., Shawver, L. K., Thurnher, A., Liang, C., Mohammadi, M., Schlessinger, J., Ullrich, A., Hubbard, S. R., Blake, R. A., et al. (2000) · PubMed · Cited by 494
Lokker, N. A., Sullivan, C. M., Hollenbach, S. J., Israel, M. A., & Giese, N. A. (2002) · PubMed · Cited by 491
Peng, B., Hayes, M., Resta, D., Racine-Poon, A., Druker, B. J., Talpaz, M., Sawyers, C. L., Rosamilia, M., Ford, J., Lloyd, P., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.050 · Cited by 472
Shapiro, W. R., Green, S. B., Burger, P. C., Mahaley, M. S., Selker, R. G., VanGilder, J. C., Robertson, J. T., Ransohoff, J., Mealey, J., Strike, T. A., et al. (1989) · Journal of Neurosurgery · doi:10.3171/jns.1989.71.1.0001 · Cited by 458
Pietras, K., Östman, A., SJÖQUIST, M., Buchdunger, E., Reed, R. K., Heldin, C., & Rubin, K. (2001) · PubMed · Cited by 450
Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy.
Pietras, K., Rubin, K., Sjöblom, T., Buchdunger, E., Sjöquist, M., Heldin, C., & Östman, A. (2002) · PubMed · Cited by 433
A comparison of numerical integrating algorithms by trapezoidal, Lagrange, and spline approximation
Yeh, K. C., & Kwan, K. C. (1978) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01066064 · Cited by 431
LAGRAN program for area and moments in pharmacokinetic analysis
Rocci, M. L., & Jusko, W. J. (1983) · Computer Programs in Biomedicine · doi:10.1016/0010-468x(83)90082-x · Cited by 414
(1992) · PubMed · Cited by 383
Rubin, B. P., Schuetze, S. M., Eary, J. F., Norwood, T. H., Mirza, S. K., Conrad, E. U., & Bruckner, J. D. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.01.027 · Cited by 364
Breedveld, P., Pluim, D., Cipriani, G., Wielinga, P., van Tellingen, O., Schinkel, A. H., & Schellens, J. H. M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2416 · Cited by 351
Houghton, P. J., Germain, G. S., Harwood, F. C., Schuetz, J. D., Stewart, C. F., Buchdunger, E., & Traxler, P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3344 · Cited by 323
BCR/ABL Regulates Mammalian RecA Homologs, Resulting in Drug Resistance
Slupianek, A., Schmutte, C., Tombline, G., Nieborowska-Skorska, M., Hoser, G., Nowicki, M. O., Pierce, A. J., Fishel, R., & Skorski, T. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00357-4 · Cited by 314
Kilic, T., Alberta, J. A., Zdunek, P. R., Acar, M., Iannarelli, P., O'Reilly, T., Buchdunger, E., Black, P. M., & Stiles, C. D. (2000) · PubMed · Cited by 310
Guha, A. R., Dashner, K., Black, P. L. M., et al. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910600206 · Cited by 296
Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib
Dewar, A. L., Cambareri, A. C., Zannettino, A. C. W., Miller, B. L., Doherty, K. V., Hughes, T. P., & Lyons, A. B. (2005) · Blood · doi:10.1182/blood-2004-10-3967 · Cited by 284
Uehara, H., Kim, S. J., Karashima, T., Shepherd, D. L., Fan, D., Tsan, R., Killion, J. J., Logothetis, C., Mathew, P., & Fidler, I. J. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.6.458 · Cited by 280
Distribution of STI-571 to the Brain Is Limited by P-Glycoprotein-Mediated Efflux
Dai, H., Marbach, P., Lemaire, M., Hayes, M., & Elmquist, W. F. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.045260 · Cited by 273
Chakravarti, A., Chakladar, A., Delaney, M. A., Latham, D. E., & Loeffler, J. S. (2002) · PubMed · Cited by 234
Response of extraabdominal desmoid tumors to therapy with imatinib mesylate
Mace, J., Sybil Biermann, J., Sondak, V., McGinn, C., Hayes, C., Thomas, D., & Baker, L. (2002) · Cancer · doi:10.1002/cncr.11029 · Cited by 193
Judson, I., Ma, P., Peng, B., Verweij, J., Racine, A., di Paola, E. D., van Glabbeke, M., Dimitrijevic, S., Scurr, M., Dumez, H., et al. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0876-0 · Cited by 193
Heuchel, R., Berg, A., Tallquist, M., Åhlén, K., Reed, R. K., Rubin, K., Claesson-Welsh, L., Heldin, C.-H., & Soriano, P. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.20.11410 · Cited by 188
Rapisarda, A., Zalek, J., Hollingshead, M., Braunschweig, T., Uranchimeg, B., Bonomi, C. A., Borgel, S. D., Carter, J. P., Hewitt, S. M., Shoemaker, R. H., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2116 · Cited by 187
Shaheen, R. M., Tseng, W. W., Davis, D. W., Liu, W., Reinmuth, N., Vellagas, R., Wieczorek, A. A., Ogura, Y., McConkey, D. J., Drazan, K. E., et al. (2001) · PubMed · Cited by 181
Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo.
Bello, L., Carrabba, G. G., Giussani, C. G., Lucini, V., Cerutti, F., Scaglione, F., Landré, J., Pluderi, M., Tomei, G., Villani, R. M., et al. (2001) · PubMed · Cited by 180
Interaction of Imatinib Mesilate with Human P-Glycoprotein
Hamada, A., Miyano, H., Watanabe, H., & Saito, H. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.055574 · Cited by 162
Hwang, R. F., Yokoi, K., Bucana, C. D., Tsan, R. Z., Killion, J. J., Evans, D. B., & Fidler, I. J. (2003) · PubMed · Cited by 158
Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity.
Russell, J. S., Brady, K. J., Burgan, W. E., Cerra, M. A., Oswald, K. A., Camphausen, K. A., & Tofilon, P. J. (2003) · PubMed · Cited by 157
STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake.
Pietras, K., Stumm, M., Hubert, M., Buchdunger, E., Rubin, K., Heldin, C., McSheehy, P. M. J., Wartmann, M., & Östman, A. (2003) · PubMed · Cited by 141
Plasma pharmacokinetics and tissue distribution of paclitaxel in CD 2 F 1 mice
Eiseman, J. L., Eddington, N. D., Leslie, J. L., MacAuley, C., Sentz, D. L., Zuhowski, M., Kujawa, J. M., Young, D., & Egorin, M. J. (1994) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00685656 · Cited by 139
Self-citationAnderson, C. M., Xiong, W., Geiger, J. D., Young, J. D., Cass, C. E., Baldwin, S. A., & Parkinson, F. E. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0730867.x · Cited by 129
Pharmacokinetics and Pharmacodynamics of Hydroxyurea
Gwilt, P. R., & Tracewell, W. G. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199834050-00002 · Cited by 117
Lü, P., Schrag, M. L., Slaughter, D. E., Raab, C. E., Shou, M., & Rodrigues, A. D. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.11.1352 · Cited by 109
Inhibition of Nucleoside Transport by Protein Kinase Inhibitors
Huang, M., Wang, Y., Cogut, S. B., Mitchell, B. S., & Graves, L. M. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.044214 · Cited by 78
Levin, V. A., & Prados, M. D. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.5.766 · Cited by 58
The Influence of Renal Function on Hydroxyurea Pharmacokinetics in Adults With Sickle Cell Disease
Yan, J., Ataga, K. I., Kaul, S., Olson, J. S., Grasela, D. M., Gothelf, S., Kutlar, A., & Orringer, E. P. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004273526 · Cited by 48
Kyritsis, A. P., Yung, W. K. A., Jaeckle, K. A., Bruner, J., Gleason, M. J., Ictech, S. E., Flowers, A., & Levin, V. A. (1996) · Neurosurgery · doi:10.1097/00006123-199611000-00006 · Cited by 32
Cited by
Wen, P. Y., & Kesari, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708126 · Cited by 3,511
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., Hahn, W. C., Ligon, K. L., Louis, D. N., Brennan, C., et al. (2007) · Genes & Development · doi:10.1101/gad.1596707 · Cited by 2,316
Glioblastoma multiforme: Pathogenesis and treatment
Alifieris, C., & Trafalis, D. T. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.05.005 · Cited by 820
Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance
Wu, W., Klockow, J. L., Zhang, M., Lafortune, F., Chang, E., Jin, L., Wu, Y., & Daldrup-Link, H. E. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105780 · Cited by 805
Larson, R. A., Druker, B. J., Guilhot, F., O'Brien, S. G., Riviere, G. J., Krahnke, T., Gathmann, I., & Wang, Y. (2008) · Blood · doi:10.1182/blood-2007-10-116475 · Cited by 643
Metadata
- Authors
- Reardon, D. A., Egorin, M. J., Quinn, J. A., Rich, J. N., Gururangan, I., Vredenburgh, J. J., Desjardins, A., Sathornsumetee, S., Provenzale, J. M., Herndon, J. E., Dowell, J. M., Badruddoja, M. A., McLendon, R. E., Lagattuta, T. F., Kicielinski, K. P., Dresemann, G., Sampson, J. H., Friedman, A. H., Salvado, A. J., & Friedman, H. S.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-12-20
- Volume
- 23
- Issue
- 36
- Pages
- 9359-9368
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2124512686
- Cited by
- 330
- References
- 59
- FWCI
- 15.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.